Form 4: Immunome Insider Sells Shares Under 10b5-1 Plan

Immunome Inc. Chief Scientific Officer Jack Higgins sold 9,438 shares of common stock for $21.64 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jack Higgins, Chief Scientific Officer at Immunome Inc., reported a transaction involving the sale of 9,438 shares of common stock.
• The sale occurred on April 2, 2026, at a price of $21.64 per share.
• This transaction was conducted under a Rule 10b5-1 trading plan, adopted by Mr. Higgins on December 19, 2025.
• Following the sale, Mr. Higgins directly beneficially owns 22,000 shares of common stock.
• Additionally, Mr. Higgins disclaims beneficial ownership of 3,000 shares held in custodial accounts for his children, which are subject to a lockup agreement entered into on December 15, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment due to the sale of shares by a key executive, despite the transaction being conducted under a pre-established 10b5-1 plan.

Positives

• The sale was executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider-information-driven trading.
• The reporting person retains a significant direct beneficial ownership of 22,000 shares after the transaction.

Negatives

• A significant number of shares were sold by a key executive.
• The sale price of $21.64 per share may indicate a valuation point for the stock at the time of the transaction.

Risks

• The shares held in custodial accounts for children are subject to a lockup agreement, which could restrict future sales or transfers.
• While executed under a 10b5-1 plan, any sale by a high-level executive can be perceived negatively by the market.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports a past transaction.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
• The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose.
• The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025.

Industry Context

StockSavvy.ai notes that insider sales, even under Rule 10b5-1 plans, are closely watched by investors. The adoption of such plans is a standard practice for executives to diversify holdings or manage personal finances without appearing to trade on material non-public information. The specific context of Immunome Inc.'s business (likely biotechnology or pharmaceuticals, given the name) means that such transactions can be sensitive to market sentiment regarding drug development pipelines and regulatory approvals.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal of reduced confidence or a need for liquidity by a key executive, potentially impacting share price in the short term.
• Employees: May view the sale with concern, especially if it occurs during periods of company-specific news or market volatility.
• Management: The transaction is a routine reporting event for management, highlighting adherence to disclosure rules.

Next Steps

• Monitor future filings for any additional transactions by Mr. Higgins or other insiders.
• Observe the market's reaction to this reported sale.

Key Dates

Recommendation

The filing reports an insider sale executed under a Rule 10b5-1 plan. While insider selling can be a negative signal, the pre-planned nature of the transaction mitigates concerns about trading on non-public information. The reporting person retains a substantial number of shares. Without further context on the company's performance or outlook, a 'hold' recommendation is appropriate, suggesting investors monitor the situation rather than making immediate decisions based solely on this transaction.

Keywords

Immunome Inc., IMNM, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Chief Scientific Officer, Beneficial Ownership, Lockup Agreement